 predict that it might address a lot of these other underlying conditions that happen along with periodontal disease. So not just the microbiome impact, but the inflammatory pathways. That underlie many age-related conditions. Rapamycin is a generic drug, so pharmaceutical companies have little incentive to fund new research.